GLP-1 vs GIP: The Two Gut Hormones Behind Modern Weight-Loss Drugs
GLP-1 and GIP are both released by your gut after eating. GLP-1 strongly suppresses appetite and slows the stomach; GIP enhances insulin response. Tirzepatide activates both, which is why it produces more weight loss than semaglutide. Triple agonists (GLP-1 + GIP + glucagon) are next.
When you hear "GLP-1 drug" you might think the only mechanism is GLP-1. The reality is more interesting. Your gut releases two main "incretin" hormones after a meal — GLP-1 and GIP — and the next generation of weight-loss drugs activates both, then a third receptor on top.
What each hormone does
GLP-1 (glucagon-like peptide-1)
- Released by L cells in the lower small intestine
- Strongly suppresses appetite (brain receptors)
- Slows gastric emptying (this is most of the "fullness")
- Stimulates insulin release in response to glucose
- Suppresses glucagon (reduces liver glucose output)
GIP (glucose-dependent insulinotropic polypeptide)
- Released by K cells in the upper small intestine
- Enhances insulin response after a meal
- Has a smaller direct appetite effect
- Affects fat storage in adipose tissue
- Less well-understood role in obesity
Why activating both matters
When researchers built tirzepatide (a single molecule that hits both receptors), the effect was larger than the sum of the parts. SURMOUNT-1 showed average 21% weight loss at 15 mg vs ~15% for semaglutide at 2.4 mg.
Theories on why:
- Complementary pathways. GLP-1 reduces intake; GIP changes how the body partitions stored vs. burned fat.
- Receptor crosstalk. Activating both may amplify hypothalamic appetite suppression beyond what either does alone.
- Better tolerability per unit effect. Some sub-analyses suggest tirzepatide patients tolerate larger weight loss with fewer side effects than would be expected on equivalent semaglutide doses.
What's next: triple agonists
Eli Lilly's retatrutide activates GLP-1, GIP, and the glucagon receptor — the triple-agonist concept. Glucagon, despite its name, has a fat-burning effect when its receptor is activated alongside the other two. Phase 2 results showed average ~24% weight loss at 48 weeks, with some patients losing more than 30%.
Other triple agonists are in development across multiple companies. Phase 3 results will land in the next few years.
Other receptor systems on the horizon
- Amylin agonists (cagrilintide). Amylin is a separate appetite hormone. Combinations with semaglutide (CagriSema) are in late-stage trials.
- GLP-1 + glucagon dual agonists (mazdutide, survodutide).
- Oral GLP-1s (oral semaglutide, Pfizer's danuglipron) — less effective than injections so far, but easier to take.
Practical implication for current patients
This matters less than the press releases suggest. Whether you're on semaglutide, tirzepatide, or eventually retatrutide:
- Stronger appetite suppression = bigger calorie deficit = more pressure on lean mass
- Same protein floor needed
- Same resistance training needed
- Same maintenance plan needed
Better drugs make the muscle-loss risk worse, not better, unless you protect against it deliberately.
Bottom line
GLP-1 and GIP are two gut hormones with overlapping but distinct effects. Tirzepatide activates both and produces more weight loss than GLP-1-only drugs. Triple-agonist drugs (adding glucagon) are coming and will produce even more weight loss. The fundamentals — protein, lifting, sleep, maintenance — apply to every generation of these drugs.